STOCK TITAN

TRACON Pharmaceuticals, Inc. - $TCON STOCK NEWS

Welcome to our dedicated page for TRACON Pharmaceuticals news (Ticker: $TCON), a resource for investors and traders seeking the latest updates and insights on TRACON Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRACON Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRACON Pharmaceuticals's position in the market.

Rhea-AI Summary

TRACON Pharmaceuticals (TCON) reported its Q1 2024 financial results, revealing cash reserves of $8 million, down from $8.6 million at the end of 2023. The company aims to leverage its Product Development Platform for non-dilutive capital. Key highlights include interim data from the ENVASARC Phase 2 trial showing an 11% ORR by investigator review and 5.5% by BICR, with a median response duration of over six months. TRACON is working to meet Nasdaq compliance requirements by June 3, 2024, following a reverse stock split and S-1 filing. R&D expenses dropped to $1.9 million from $5 million YoY, and net loss decreased to $3.2 million from $8.5 million YoY.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.77%
Tags
-
Rhea-AI Summary

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) will report its first quarter 2024 financial results on May 14, 2024. The company utilizes a cost-efficient product development platform to advance cancer therapeutics and partner with life science companies. Management will host a conference call to discuss financial results and corporate activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
conferences earnings
-
Rhea-AI Summary
TRACON Pharmaceuticals (TCON) announces a reverse stock split at a ratio of one-for-twenty, effective April 9, 2024. The company's common stock will trade on a split-adjusted basis starting April 10, 2024, under the symbol 'TCON'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.2%
Tags
Rhea-AI Summary
TRACON Pharmaceuticals (NASDAQ: TCON) announces the ENVASARC Phase 2 trial completion with positive interim results. Envafolimab shows promising efficacy and safety profile in treating sarcoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-47.24%
Tags
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (TCON) announced financial results for Q4 and year-end 2023, highlighting progress in the ENVASARC trial with envafolimab. The company reported positive ORR data and plans to complete enrollment of 80 patients this quarter. TRACON aims to leverage its Product Development Platform for non-dilutive capital generation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) will report its Q4 and year-end 2023 financial results on March 5, 2024. The company focuses on developing novel cancer therapeutics and partnering with life science firms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
conferences earnings
Rhea-AI Summary
TRACON Pharmaceuticals (NASDAQ: TCON) announced that the ongoing pivotal Phase 2 ENVASARC trial has enrolled more than 70 of the 80 planned patients in Cohort C of single agent envafolimab treatment at a dose of 600 mg subQ every three weeks. The objective response rate (ORR) by investigator review increased to 15% since the interim analysis in September. Full ENVASARC enrollment is expected in 1Q 2024, and final data is anticipated during 3Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announces the licensing of its proprietary CRO-independent product development platform (PDP) to a clinical stage biotech company for a $3.0 million upfront payment. This move aims to allow other companies to benefit from TRACON's cost-efficient and shorter clinical trial timelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced their third quarter financial results, highlighting progress in the ENVASARC trial for envafolimab, a novel targeted cancer therapeutic. The company also reported upcoming milestones and positive financial results, including a net income of $10.8 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.75%
Tags
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. will report its third quarter 2023 financial and operating results on November 9, 2023. The company utilizes a cost-efficient, CRO-independent product development platform for cancer therapeutics. A conference call will be held to discuss the financial results and provide an update on corporate activities. Registration is required to participate in the live call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
conferences earnings
TRACON Pharmaceuticals, Inc.

Nasdaq:TCON

TCON Rankings

TCON Stock Data

4.02M
2.08M
2.6%
11.66%
1.64%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
San Diego

About TCON

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w